Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3

被引：0
|
作者：
Touzeau, Cyrille [1 ]
Weisel, Katja [2 ]
Bahlis, Nizar [3 ]
Quach, Hang [4 ]
Hamilton, Finn [5 ]
Wang, Shen-wu [5 ]
Leip, Eric [5 ]
Viqueira, Andrea [6 ]
O'Brien, Thomas [5 ]
Rodriguez-Otero, Paula [7 ]
机构：
[1] CHU Nantes, Nantes, France
[2] Univ Canc Ctr Hamburg, Hamburg, Germany
[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[4] Univ Melbourne, Vincents Hosp Melbourne, Parkville, Vic, Australia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer SLU, Madrid, Spain
[7] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort a of MagnetisMM-3
    Shay, Gemma
    Bahlis, Nizar
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 16 - 17
  • [2] Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3
    Iida, Shinsuke
    Ito, Satoshi
    Yokoyama, Hisayuki
    Ishida, Tadao
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Suzuki, Kenshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 991 - 1000
  • [3] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
    Alexander M. Lesokhin
    Michael H. Tomasson
    Bertrand Arnulf
    Nizar J. Bahlis
    H. Miles Prince
    Ruben Niesvizky
    Paula Rodrίguez-Otero
    Joaquin Martinez-Lopez
    Guenther Koehne
    Cyrille Touzeau
    Yogesh Jethava
    Hang Quach
    Julien Depaus
    Hisayuki Yokoyama
    Afshin Eli Gabayan
    Don A. Stevens
    Ajay K. Nooka
    Salomon Manier
    Noopur Raje
    Shinsuke Iida
    Marc-Steffen Raab
    Emma Searle
    Eric Leip
    Sharon T. Sullivan
    Umberto Conte
    Mohamed Elmeliegy
    Akos Czibere
    Andrea Viqueira
    Mohamad Mohty
    Nature Medicine, 2023, 29 : 2259 - 2267
  • [4] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
    Lesokhin, Alexander H.
    Tomasson, Michael
    Arnulf, Bertrand J.
    Bahlis, Nizar
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Touzeau, Cyrille
    Jethava, Yogesh
    Quach, Hang
    Depaus, Julien
    Yokoyama, Hisayuki
    Gabayan, Afshin Eli A.
    Stevens, Don K.
    Nooka, Ajay
    Manier, Salomon
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Searle, Emma
    Leip, Eric T.
    Sullivan, Sharon
    Conte, Umberto
    Elmeliegy, Mohamed
    Czibere, Akos
    Viqueira, Andrea
    Mohty, Mohamad
    NATURE MEDICINE, 2023, 29 (09) : 2259 - +
  • [5] A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Noopur, Raje
    Xavier, Leleu
    Alexander, Lesokhin M.
    Mohamed, Mohty
    Ajay, Nooka
    Eric, Leip
    Umberto, Conte
    Andrea, Vlqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S17 - S18
  • [6] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [7] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [8] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
    Tomasson, Michael H.
    Iida, Shinsuke
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Rodriguez-Otero, Paula
    Miles Prince, H.
    Viqueira, Andrea
    Leip, Eric
    Conte, Umberto
    Sullivan, Sharon T.
    Lesokhin, Alexander M.
    HEMASPHERE, 2024, 8 (07):
  • [10] MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
    Prince, H. Miles
    Bahlis, Nizar J.
    Rodriguez-Otero, Paula
    Karlin, Lionel
    Akard, Luke
    Varshavsky-Yanovsky, Asya
    Chu, Michael P.
    Nagai, Yuya
    Vesole, David H.
    Hickman, Anne
    Sullivan, Sharon T.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander M.
    BLOOD, 2024, 144 : 4738 - 4739
12345